The Study Of ET, VEGF And MVD Expression In Endometrial Carcinoma Tissue

Objective: Endometria carcinoma is one of the most common gynecological tumors of genital duct in Euro- American countries. In recent years, the morbidity is up-trend in our country. Therefore, the study of tumor is increasingly becoming a hot issue for scholars all over the world. The development,infiltration and metastasis of tumor cell is a complex and continuous process. It is closely correlated between neovascularization and tumor growth metastasis. People have found in the latest years that many factors are correlated with tumor vascularization. This study is to investigate the expression of ET, VEGF, MVD, apoptosis, cell cycle in proliferative phase of endometrium(PPE), hyperplasia of endometrium(HE) and endometrial carcinoma(EC), and the effect on the prognosis in PPE, HE and EC to provide a theoretical basis for clinical treatment and predicting prognosis.Methods: The expression of ET, VEGF, MVD were detected by immunohistochemical method (SP) in PPE, HE and EC. The expression of ET, the apoptosis ratio and cell proliferation index were detected by FCM in PPE, HE and EC. All data were analysed by SPSS12.0 for Windows.Results: 1 The immunohistochemical staining result: In EC, HE and PPE, the positive rate of ET expression are 83.3%, 50%, 10% and there is obviously distinct among them (P<0.01). In EC, grade 1 is 80.0%, and grade 2-3 is 85.2%, and there is no obvious distinction among them (P>0.05). The positive rate of ET expression is 75.0% when not more than 50 percent myometrium is infiltrated in endometrial cancer, and 100% is expressed when more than 50 percent myometrium is infiltrated. There is obvious distinction between them (P<0.05). The positive rate of ET in endometrial cancer without tumor embolus is 73.1%. While with tumor embolus is 100%. There is obvious distinction between them(P<0.05). Among different pathological stage, and stage I is 78.6%, stage II-III is 92.9%, and there is no obvious distinction among them (P>0.05).In EC, HE and PPE, the positive rate of VEGF expression are 81.0%, 56.3%, 10%. There is obvious distinction between them(P<0.01). In EC, grade 1 is 73.3%, and grade 2-3 is 85.2%, and there is no obvious distinction among them (P>0.05). The positive rate of VEGF expression is 71.4% when not more than 50 percent myometrium is infiltrated in endometrial cancer, and 100% is expressed when more than 50 percent myometrium is infiltrated. There is obvious distinction between them (P<0.05). The positive rate of VEGF in endometrial cancer without tumor embolus is 69.2%. While with tumor embolus is 100%.There is obvious distinction between them(P<0.05). Among different pathological stage, stage I is 75.0%, and stage II-III is 92.9%, and there is no obvious distinction among them (P>0.05). In EC, HE and PPE, MVD are (18.17±1.82), (16.00±1.97), (12.40±2.01). There is obvious distinction between them(P<0.01). In EC, grade 1 is (17.60±1.80), and grade 2-3 is (18.48±1.78), and there is no obvious distinction among them (P>0.05). The MVD is (17.75±1.96) when not more than 50 percent myometrium is infiltrated in endometrial cancer, and (19.00±1.18) when more than 50 percent myometrium is infiltrated. There is obvious distinction between them (P<0.05). The MVD in endometrial cancer without tumor embolus is (17.47±1.84), While with tumor embolus is (19.31±1.08). There is obvious distinction between them(P<0.05). Among different pathological stage, stage I is (17.86±1.92), and stage II-III is (18.79±1.48), and there is no obvious distinction among them (P>0.05).There is correlation between ET and VEGF (r=0.884, P<0.01) in proliferative phase of endometrium, hyperplasia of endometrium and endometria carcinoma.2 The protein relative level detected by FCM: In EC, HE and PPE , the protein relative level of ET are (4.40±0.30), (3.99±0.26), (3.48±0.29) and the difference is significant (P<0.01). In EC, among different pathological stage, stage I is (4.35±0.29), and stage II-III is (4.50±0.29), and there is no obvious distinction among them (P>0.05). The ET are (4.29±0.23) when not more than 50 percent myometrium is infiltrated in endometrial cancer, and (4.62±0.30) when more than 50 percent myometrium is infiltrated. There is obvious distinction between them (P<0.05). The ET in endometrial cancer without tumor embolus is (4.28±0.21). While with tumor embolus is (4.59±0.31). There is obvious distinction between them (P<0.05). Grade 1 is (4.30±0.24), and grade 2-3 is (4.45±0.32), and there is no obvious distinction among them (P>0.05). The results were consistent with immunohistochemistic results. In EC, HE and PPE, the proliferation index are (48.74±2.05), (44.41±2.14), (41.57±2.97) and the differences are significant (P<0.01). In EC, among different pathological stage, and stage I is (48.61±1.93), and stage II-III is (49.00±2.31), and there is no obvious distinction among them (P>0.05). The proliferation index are (47.67±1.55) when not more than 50 percent myometrium is infiltrated in endometrial cancer, and (50.91±0.82) when more than 50 percent myometrium is infiltrated.There is obvious distinction between them (P<0.05). The proliferation index in endometrial cancer without tumor embolus is (47.67±1.67). While with tumor embolus is (50.49±1.26). There is obvious distinction between them(P<0.05). Grade 1 is (48.33±1.75), and grade 2-3 is (48.98±2.19), and there is no obvious distinction among them (P>0.05).In EC, HE and PPE, the apoptosis ratio are (17.67±1.76), (14.86±2.09), (11.49±1.90) and the difference is significant (P<0.01). In EC, among different pathological stage, stage I is (17.50±1.81), and stage II-III is (18.00±1.67), and there is no obvious distinction among them (P>0.05). The apoptosis ratio are (16.86±1.34) when not more than 50 percent myometrium is infiltrated in endometrial cancer, and (19.27±1.35) when more than 50 percent myometrium is infiltrated. There is obvious distinction between them (P<0.05). The apoptosis ratio in endometrial cancer without tumor embolus is (16.84±1.35). While with tumor embolus is (19.02±1.51). There is obvious distinction between them(P<0.05). Grade 1 is (17.15±1.24), and grade 2-3 is (17.95±1.95), and there is no obvious distinction among them (P>0.05).There is correlation between ET and proliferation index and apoptosis in proliferative phase of endometrium, hype- plasia of endometrium and endometria carcinoma(P<0.01).Conclusions: This study proved it is increasing for the expression of ET, VEGF, MVD, proliferation index and apop- tosis ratio in PPE, HE and EC. In endometria carcinoma, the expression of ET, VEGF, MVD, proliferation index and apop- tosis is increasing with the infiltrated depth and tumor embolus. This indicates that ET and VEGF are essential for the carcinogenesis, development, infiltration and metastasis of carcinoma of endometrium, and they interacted each other. ET and VEGF have been turned out to play an essential role in the matastasis in carcinoma of endometrium.By studing ET, VEGF and MVD in endometrial cancer, we conclude their effects on growth, infiltrated ability and metastasis of endometrial cancer. It can offer a basis of detecting invasion and metastasis of endometrial cancer. It also can provide a guide for special treatment of endometrial cancer.